Sign In  |  Register  |  About Los Altos  |  Contact Us

Los Altos, CA
September 01, 2020 1:26pm
7-Day Forecast | Traffic

  • Search Hotels in Los Altos

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Affini-T Therapeutics, Inc.

Affini-T Therapeutics to Present Trial-in-Progress Poster and Preclinical Data from Its Oncogenic Driver Programs Targeting TP53 R175H, KRAS G12D and KRAS-G12V at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
From Affini-T Therapeutics, Inc.
Via Business Wire
Affini-T Therapeutics Announces First Patient Dosed in KRAS G12V Phase 1 Program and Presentation of Trial-in-Progress Poster at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
From Affini-T Therapeutics, Inc.
Via Business Wire
Affini-T Therapeutics to Present Data From Its Preclinical Programs Targeting KRAS G12D and TP53 R175H at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting
From Affini-T Therapeutics, Inc.
Via Business Wire
Affini-T Therapeutics Presents Preclinical Data from its Oncogenic Driver Programs Targeting KRAS G12D and p53 R175H at the American Association for Cancer Research (AACR) Annual Meeting 2024
From Affini-T Therapeutics, Inc.
Via Business Wire
Affini-T Therapeutics to Present Preclinical Data from its Programs Targeting KRAS G12D and p53 R175H and Two Trials in Progress at the American Association for Cancer Research (AACR) Annual Meeting
From Affini-T Therapeutics, Inc.
Via Business Wire
Affini-T Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Affini-T Therapeutics, Inc.
Via Business Wire
Affini-T Therapeutics Appoints Healthcare Capital Markets Veteran Kathy Bergsteinsson, MBA, as Chief Financial Officer
From Affini-T Therapeutics, Inc.
Via Business Wire
Affini-T Therapeutics to Present Preclinical Gene Editing Data from its Program Targeting KRAS G12D at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
From Affini-T Therapeutics, Inc.
Via Business Wire
Affini-T Therapeutics Appoints Industry Veteran Thaminda Ramanayake, M.S., MBA, as Chief Business Officer
From Affini-T Therapeutics, Inc.
Via Business Wire
Affini-T Therapeutics to Present AFNT-211 T Cell Product Attributes Targeting KRAS G12V at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
From Affini-T Therapeutics, Inc.
Via Business Wire
Affini-T Therapeutics to Present Novel CRISPR Gene Editing Data from its Oncogenic Driver Program Targeting KRAS at the American Society of Gene and Cell Therapy 26th Annual Meeting
From Affini-T Therapeutics, Inc.
Via Business Wire
Affini-T Therapeutics Announces Licensing Agreement with Leading Comprehensive Cancer Center to Expand Company’s Pipeline of Oncogenic Driver Programs
From Affini-T Therapeutics, Inc.
Via Business Wire
Affini-T Therapeutics Presents Preclinical Data from its Oncogenic Driver Program Targeting KRAS at the American Association for Cancer Research (AACR) Annual Meeting 2023
From Affini-T Therapeutics, Inc.
Via Business Wire
Affini-T Therapeutics to Present Preclinical Data from its Oncogenic Driver Program Targeting KRAS at the American Association for Cancer Research (AACR) Annual Meeting 2023
From Affini-T Therapeutics, Inc.
Via Business Wire
Affini-T Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Affini-T Therapeutics, Inc.
Via Business Wire
Affini-T Therapeutics to Present Preclinical Data from its Lead Programs Targeting KRAS G12V at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
From Affini-T Therapeutics, Inc.
Via Business Wire
Affini-T Therapeutics Named to the 2022 Endpoints 11
From Affini-T Therapeutics, Inc.
Via Business Wire
Affini-T Therapeutics Appoints Pioneering T Cell Therapy and KRAS Developer Dirk Nagorsen, M.D., as Chief Medical Officer
From Affini-T Therapeutics, Inc.
Via Business Wire
Affini-T Therapeutics Appoints Jill DeSimone to its Board of Directors
From Affini-T Therapeutics, Inc.
Via Business Wire
Affini-T Therapeutics to Present at Upcoming Investor and Industry Conferences
From Affini-T Therapeutics, Inc.
Via Business Wire
Affini-T Therapeutics’ KRAS TCR T Cell Therapy Program to be Presented at the Annual Meeting of the American Society of Gene and Cell Therapy
From Affini-T Therapeutics, Inc.
Via Business Wire
Affini-T Therapeutics Completes $175 Million Financing Co-Led by Vida Ventures and Leaps by Bayer to Advance Groundbreaking T Cell Therapies for Solid Tumor Patients with Oncogenic Driver Mutations
From Affini-T Therapeutics, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 LosAltos.com & California Media Partners, LLC. All rights reserved.